Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

CT Open to Enrollment

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

This clinical trial is for men and women with newly diagnosed or relapsed/refractory acute myeloid leukemia.

The purpose of this study is to determine a safe dose of an investigational new drug (ziftomenib) in combination with other study drugs i.e., venetoclax and azacitidine or cytarabine plus daunorubicin. This will include an evaluation of side effects associated with ziftomenib in combination with the other study drugs and also aims to determine how ziftomenib works in combination with the other study drugs.

APEC1621C NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL

The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that “target” those changes. This combination of a tumor with a mutation and a drug that aims at that mutation is called a “match.” There are two steps for participants in this study.
   

A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

The purpose of this study is to test the safety of the anti-cancer immunotherapy drug called nivolumab in patients with cancer and autoimmune disorders. This study is part of a larger study that looks at several different autoimmune disorders including Systemic lupus erythematosus, Dermatomyositis/systemic sclerosis, Multiple sclerosis, Rheumatoid arthritis, Ulcerative colitis, Crohn's disease, Sjogren's syndrome, Psoriasis, Psoriatic arthritis or other autoimmune diseases not specified. 
   

Pilot Study of PSMA-TRT Re-treatment Utilizing 225Ac-J591

This is a pilot study of single dose of 225Ac-J591 at 90 KBq/Kg in men with progressive metastatic castration resistant prostate cancer (mCRPC).

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

The study will test an investigational product called VCN-01 in patients with metastatic pancreatic cancer. “Investigational” means that VCN-01 has not been approved by the U.S. Food and Drug Administration (FDA) to treat any disease.

Preserving Erectile Function by Quantifying the Nerve-Sparing Step of the Robotic Prostatectomy

Our broad objective is to quantify surgeon performance, build automated assessments grounded in patient-centered outcomes, and develop quality assurance programs to improve training for surgeons.
   

In Vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound

The purpose of this study is to determine the effectiveness of a new ultrasound technique to detect cancer and/or other abnormalities in lymph nodes, small bean-shaped structures that are part of the body's immune system. Participants in this study will have at least one lymph node that may be larger than normal.